Several institutional investors have adjusted their holdings in AbbVie (ABBV). Vermillion & White Wealth Management and Fairway Wealth each invested about $26,000. Ridgewood Investments invested around $27,000, while Able Wealth Management invested approximately $33,000. IFS Advisors entered with a stake of around $36,000. Overall, institutional investors own 70.23% of AbbVie.
AbbVie Stock Insights
As of Thursday, ABBV opened at $196.74, with a market cap of $347.42 billion. Key metrics include a P/E ratio of 58.38 and a beta of 0.64. AbbVie has a 52-week range of $135.85 to $199.95.
Recent Earnings
On July 25th, AbbVie reported a quarterly EPS of $2.65, exceeding analyst expectations. The companys revenue was $14.46 billion, up 4.3% year-over-year. Analysts predict an EPS of 10.86 for the current year.
Dividend Update
AbbVie declared a quarterly dividend of $1.55, payable on November 15th, with an annual yield of 3.15%.
Analyst Opinions
Analysts have boosted their price targets for AbbVie: Piper Sandler to $209, Truist to $210, and BMO Capital to $214. Currently, the average recommendation is “Buy” with a target of $191.64.
Insider Transactions
Chairman Richard A. Gonzalez sold 66,500 shares on August 5th for $12.4 million, and another 282,845 shares on July 17th for $49.5 million. Insiders own 0.25% of AbbVie.
About AbbVie
AbbVie Inc. develops and sells pharmaceutical products, including Humira for autoimmune diseases and Rinvoq for arthritis.
Featured Articles
- Five Stocks Better Than AbbVie
- Economic Reports and Investment Strategies
- Top Stocks with Potential Upside
- Understanding Consumer Discretionary Stocks
- Buying Opportunities Post-Earnings Drop
- P&G: A Buy Before New Highs
- Microsoft’s Promising Upside
Receive Daily News & Ratings for AbbVie – Enter your email below for the latest updates and analyst ratings from MarketBeat.com’s FREE daily newsletter.
`
